Context Therapeutics (CNTX) Provides ONA-XR Clinical Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
November 21, 2022 9:12 AM ESTCompany reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented
PHILADELPHIA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Context or the Company) (Nasdaq: CNTX), a womens oncology company developing novel treatments for breast and gynecologic cancers, today announced clinical data on onapristone extended release (ONA-XR) will be presented at the 2022 San Antonio Breast Cancer Symposium® (SABCS®) taking place in San Antonio, Texas, from December 6-10, 2022.
We are pleased that ONA-XR will be featured at SABCS. Initial... More
